The German BioNTech biotechnology laboratory announced today that it intends to open regional offices and set up a vaccine factory based on mRNA technology in Singapore, where hundreds of millions of doses of its covid-19 vaccine will be produced, according to the RES.
BioNTech “intends to set up a mRNA vaccine production facility in Singapore” in order to be able to “immediately address the risk of a pandemic, if necessary,” it said in a statement.
The German laboratory expects that this plant will be fully operational in 2023 and will create up to 80 jobs in Singapore.
It will be BioNTech’s first plant outside Europe, after its one in Marburg, Germany, while in 2020 it opened offices in Cambridge, Massachusetts, USA.
Its partner, the American Pfizer, has a production plant in the USA and another in Poor, Belgium.
Last week, the German lab announced it would make up to 3 billion doses of its covid-19 vaccine this year and more than 3 billion a year.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
